Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03267498 · ClinicalTrials.gov registry record · Phase 2
Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)
A Phase 2 study, sponsored by Sue Yom.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT03267498 is a Phase 2 study that has completed, run by Sue Yom. The registered enrollment target is 40 participants.
The verdict
NCT03267498, a Phase 2 study, has completed, sponsored by Sue Yom.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This phase II trial studies how well nivolumab and chemoradiotherapy works in treating patients with stage II-IVB nasopharyngeal cancer. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells. Chemoradiotherapy is the combination of chemotherapy and radiation therapy and may prevent the cancer from spreading when combined with nivolumab. Giving nivolumab and chemoradiotherapy may work better in treating patients with stage II-IVB nasopharyngeal cancer.
Interventions
- DRUG Cisplatin
- DRUG Nivolumab
- RADIATION Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-02-14 |
| Est. Completion | 2024-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03267498
The ClinicalTrials.gov registry entry for NCT03267498 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sue Yom, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT03267498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03267498 about?
NCT03267498 is a clinical study titled "Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)". This phase II trial studies how well nivolumab and chemoradiotherapy works in treating patients with stage II-IVB nasopharyngeal cancer. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells. Chemoradiotherapy is the combination of chemotherapy...
What is the current status of trial NCT03267498?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2018-02-14. Estimated completion is 2024-10-31.
What interventions are being tested in trial NCT03267498?
The interventions under investigation include: Cisplatin (DRUG), Nivolumab (DRUG), Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT03267498?
This trial is sponsored by Sue Yom, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.